lenalidomide (STAR-LLD-OBDS) / Starton Therap - LARVOL DELTA

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) (clinicaltrials.gov) - P1/2 | N=24 | Recruiting | Sponsor: Starton Therapeutics, Inc | Trial completion date: Mar 2027 ➔ Mar 2028 | Trial primary completion date: May 2026 ➔ May 2027

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Continuous subcutaneous lenalidomide delivery improves the therapeutic index and avoids drug-related grade 3/4 hematologic toxicity in patients with relapsed/refractory multiple myeloma (AACR 2025) - "Four patients were previously exposed to Len, one of which was discontinued from a prior regimen because of severe fatigue, and 6 had received prior bortezomib... Continuous delivery of low dose Len provides meaningful efficacy and improved tolerability with no grade >3 drug-related hematologic toxicity. Further studies in MM and chronic lymphocytic leukemia are planned."

Clinical • Late-breaking abstract • Chronic Lymphocytic Leukemia • Hematological Malignancies • Multiple Myeloma • Oncology